Sierra's Wegovy side effects after 18 months, fact-checked
Quick answer
Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite for weight management. Clinical trials show side effects typically peak during the first 16-20 weeks of dose escalation, then diminish but may persist at lower rates. The STEP 1 trial found 14.9% average weight loss at 68 weeks with an 83.5% completion rate.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this TikTok creator claim?
@sierra.robichaud says her Wegovy side effects are "pretty mild" and "very manageable" after 18 months on the medication. She contrasts this with more difficult side effects early in her treatment journey.
The video shows her discussing ongoing side effects but emphasizes they've become easier to handle over time. Sierra suggests this improvement makes continuing the medication straightforward for her.
Does the timeline match what we know about Wegovy?
Yes, Sierra's experience matches clinical trial data showing side effects typically peak early then diminish. The STEP 1 trial (Wilding et al., NEJM, 2021) found most gastrointestinal side effects occurred during dose escalation in the first 16-20 weeks.
Nausea affected 44.2% of participants on 2.4mg semaglutide versus 16.6% on placebo. But these rates dropped significantly after reaching maintenance dose. Vomiting peaked at 24.6% during escalation, then fell to single digits by week 68.
The study's withdrawal rate tells a similar story. Most people who quit due to side effects (7% total) did so in the first six months, not after sustained treatment.
What about her claim that side effects are "manageable"?
This is subjective but supported by real-world data. The STEP trials showed 83.5% of people stayed on 2.4mg semaglutide for the full 68 weeks, suggesting most found side effects tolerable long-term.
However, Sierra doesn't mention what specific side effects she's experiencing now. The most common persistent effects in trials were nausea (17.4% at one year), diarrhea (11.5%), and constipation (11.1%).
Her experience isn't universal though. About 4.5% of STEP 1 participants stopped treatment due to gastrointestinal issues that didn't resolve. Some people never adapt to the medication.
What's missing from her take?
Sierra focuses entirely on tolerability without discussing effectiveness maintenance. The STEP extension study (Rubino et al., Diabetes Care, 2022) showed people regained about two-thirds of lost weight when stopping semaglutide after one year.
She also doesn't mention the need for ongoing medical monitoring. Long-term Wegovy users need regular check-ins for potential issues like gallbladder problems, which occurred in 2.6% of STEP 1 participants versus 1.2% on placebo.
The cost factor gets ignored too. At roughly $1,300 monthly without insurance coverage, "easy to continue" assumes significant financial resources most people don't have.
What should you actually expect on Wegovy?
Most people do see side effects improve after the initial dose escalation period, just like Sierra describes. But don't expect them to disappear completely.
The STEP 1 data shows about 15-20% of people still experience nausea at one year. Digestive issues remain the most common ongoing complaints. Some people develop new side effects like hair loss or changes in taste.
If you're considering Wegovy, discuss realistic expectations with your doctor. The medication works best when combined with lifestyle changes, and stopping it typically leads to weight regain. Sierra's positive experience is encouraging but not guaranteed for everyone.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Sierra's Wegovy side effects after 18 months, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Wegovy (semaglutide 2.
FormBlends verdict
Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite for weight management. Clinical trials show side effects typically peak during the first 16-20 weeks of dose escalation, then diminish but may persist at lower rates. The STEP 1 trial found 14.9% average weight loss at 68 weeks with an 83.5% completion rate.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite for weight management. Clinical trials show side effects typically peak during the first 16-20 weeks of dose escalation, then diminish but may persist at lower rates. The STEP 1 trial found 14.9% average weight loss at 68 weeks with an 83.5% completion rate.
- STEP 1 trial data confirms Wegovy side effects typically peak in the first 16-20 weeks then diminish significantly
- 83.5% of participants completed the full 68-week STEP 1 study, suggesting most people can tolerate long-term treatment
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- STEP 1 trial data confirms Wegovy side effects typically peak in the first 16-20 weeks then diminish significantly
- 83.5% of participants completed the full 68-week STEP 1 study, suggesting most people can tolerate long-term treatment
- About 15-20% of users still experience nausea and other GI side effects at one year of treatment
- 7% of STEP 1 participants withdrew due to side effects, mostly in the first six months
- Stopping semaglutide leads to regaining about two-thirds of lost weight according to extension studies
- Long-term users need medical monitoring for potential complications like gallbladder problems (2.6% incidence)
- Monthly Wegovy costs around $1,300 without insurance coverage, making "easy to continue" financially dependent
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Sierra · TikTok creator
888.1K views on this video
These are all the side effects on Wegovy after a year and a half of taking the medication. It’s been pretty mild which is a huge difference from the beginning of my Wegovy journey. Everything is very
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Sierra, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.